Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2(diphenylmethoxy)ethyl]-4-(3-phenyl-2- propenyl)piperazine], and the neuronal transporter of dopamine

Journal of Neurochemistry

Volumn 72, Issue 1, 1999, Pages 396-404

  Do Régo, Jean Claude ^a   Hue, Hervé ^b   Costentin, Jean ^a   Bonnet, Jean Jacques ^a,c  

^a UPRESA CNRS 6036   (France)

^b Lab d'Appl des Mathematiques   (France)

^c UPRESA CNRS 6036   (France)

Author keywords

Dopamine neuronal transporter; GBR 12783; Kinetics; Rat; Uptake inhibitor

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; COCAINE; DOPAMINE; TRITIUM;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABUSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES; TIME FACTORS;

ANIMALIA; TRITIUM;

EID: 0345435178     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0720396.x     Document Type: Article

References (30)

1. Andersen P. H. (1989) The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur. J. Pharmacol. 166, 493-504.
2. 3H]GBR 12783 to the dopamine neuronal carrier included in polarized membranes. Eur. J. Pharmacol. 247, 333-340.
3. Billaud G., Menard J.-F., Marcellin N., Kamenka J.-M., Costentin J., and Bonnet J.-J. (1994) Thermodynamics of the binding of BTCP (GK13) and related derivatives on the dopamine neuronal carrier. Eur. J. Pharmacol. 268, 357-363.
4. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 12, 27-36.
5. Bonnet J.-J. and Costentin J. (1986) GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo. Eur. J. Pharmacol. 121, 199-209.
6. Bonnet J.-J., Lemasson M.-H., and Costentin J. (1984) Simultaneous evaluation by a double labelling method of drug-induced uptake inhibition and release of dopamine in synaptosomal preparation of rat striatum. Biochem. Pharmacol. 33, 2129-2135.
7. 3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system. Eur. J. Pharmacol. 126, 211-222.
8. 3H]mazindol. J. Pharmacol. Exp. Ther. 253, 1206-1214.
9. Carroll F. I., Lewin A. H., and Kuhar M. J. (1997) Dopamine transporter uptake blockers. Structure-activity relationships, in Neurotransmitter Transporters. Structure, Function and Regulation (Reith M. E. A., ed). pp. 263-295. Humana Press, Totowa, New Jersey.
10. 3H]dopamine in rat brain tissue slices. Biochem. Pharmacol. 24, 847-852.
11. Héron C., Costentin J., and Bonnet J.-J. (1994) Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur. J. Pharmacol. 264, 391-398.
12. 3H]GBR 12783 binding to the dopamine neuronal carrier. Eur. J. Pharmacol. 301, 195-202.
13. Kuhar M. J., Ritz M. C., and Boja J. W. (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14, 299-302.
14. Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
15. 3H]Cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 251, 131-141.
16. Morrison J. F. and Walsh C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors, in Advances in Enzymology and Related Areas of Molecular Biology, Vol. 61 (Meister A., ed), pp. 201-301. J. Wiley and Sons, New York.
17. Raiteri M., Cerrito F., Cervoni A. M., and Levi G. (1979) Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208, 195-202.
18. 3H]cocaine in mouse striatum and cerebral cortex have different dissociation kinetics. J. Neurochem. 46, 309-312.
19. Ritz M. C., Lamb R. J., Goldberg S. R., and Kuhar M. J. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223.
20. Rocha B. A., Fumagalli F., Gainetdinov R. R., Jones S. R., Ator R., Giros B., Miller G. W., and Caron M. G. (1998) Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1, 132-137.
21. Rothman R. B., Mele A., Reid A. A., Akunne H., Greig N., Thurkauf A., Rice K. C., and Pert A. (1989) Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development. FEBS Lett. 257, 341-344.
22. Rothman R. B., Mele A., Reid A. A., Akunne H. C., Greig N., Thurkauf A., De Costa B. R., Rice K. C., and Pert A. (1991) GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav. 40, 387-397.
23. Saadouni S., Refahi-Lyamani F., Costentin J., and Bonnet J.-J. (1994) Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier. Eur. J. Pharmacol. 268, 187-197.
24. Schwarz G. (1978) Estimating the dimension of a model. Ann. Stat. 6, 461-464.
25. Szedlacsek S. E. and Duggleby R. G. (1995) Kinetics of slow and tight-binding inhibitors, in Methods in Enzymology, Vol. 249 (Purich D. L., ed), pp. 144-180. Academic Press, San Diego.
26. Trendelenburg U. (1991) Functional aspects of the neuronal uptake of noradrenaline. Trends Pharmacol. Sci. 121, 334-337.
27. Van der Zee P., Koger H. S., Gootjes J., and Hespe W. (1980) Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 15, 363-370.
28. 3H]BTCP: a new phencyclidine analog selective for the dopamine uptake complex. Eur. J. Pharmacol. 148, 427-436.
29. Xu C., Coffey L. L., and Reith M. E. A. (1995) Translocation of dopamine and binding of 2β-carbomethoxy-3β-(4-fluorophenyl)-tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem. Pharmacol. 49, 339-350.
30. Zimanyi I., Lajtha A., and Reith M. E. A. (1989) Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn Schmiedebergs Arch. Pharmacol. 340, 626-632.